DIEFENHARDT, Markus, SCHLENSKA-LANGE, Anke, KUHNT, Thomas, KIRSTE, Simon, PISO, Pompiliu Ioan, BECHSTEIN, Wolf Otto, HILDEBRANDT, Guido, GHADIMI, Michael, HOFHEINZ, Ralf-Dieter, RÖDEL, Claus, FOKAS, Emmanouil und GERMAN RECTAL CANCER STUDY GROUP, 2022. Total neoadjuvant therapy for rectal cancer in the CAO/ARO/AIO-12 randomized phase 2 trial: early surrogate endpoints revisited. Freiburg: Universität.

Diefenhardt, M., Schlenska-Lange, A., Kuhnt, T., Kirste, S., Piso, P.I., Bechstein, W.O., Hildebrandt, G., Ghadimi, M., Hofheinz, R.-D., Rödel, C., Fokas, E., German Rectal Cancer Study Group, 2022. Total neoadjuvant therapy for rectal cancer in the CAO/ARO/AIO-12 randomized phase 2 trial: early surrogate endpoints revisited. Universität, Freiburg. https://doi.org/10.3390/cancers14153658

Diefenhardt, M., Schlenska-Lange, A., Kuhnt, T., Kirste, S., Piso, P. I., Bechstein, W. O., Hildebrandt, G., Ghadimi, M., Hofheinz, R.-D., Rödel, C., Fokas, E., & German Rectal Cancer Study Group. (ca. 2022). Total neoadjuvant therapy for rectal cancer in the CAO/ARO/AIO-12 randomized phase 2 trial: early surrogate endpoints revisited [Cd]. Universität. https://doi.org/10.3390/cancers14153658

Diefenhardt M, Schlenska-Lange A, Kuhnt T, Kirste S, Piso PI, Bechstein WO, Hildebrandt G, Ghadimi M, Hofheinz R-D, Rödel C, Fokas E, German Rectal Cancer Study Group (2022) Total neoadjuvant therapy for rectal cancer in the CAO/ARO/AIO-12 randomized phase 2 trial: early surrogate endpoints revisited. Universität, Freiburg

Diefenhardt, Markus/ Schlenska-Lange, Anke/ Kuhnt, Thomas/ Kirste, Simon/ Piso, Pompiliu Ioan/ Bechstein, Wolf Otto/ Hildebrandt, Guido/ Ghadimi, Michael/ Hofheinz, Ralf-Dieter/ Rödel, Claus/ Fokas, Emmanouil/ German Rectal Cancer Study Group, Total neoadjuvant therapy for rectal cancer in the CAO/ARO/AIO-12 randomized phase 2 trial: early surrogate endpoints revisited, Freiburg 2022.